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Behçet’s disease (BD) is an immune-mediated vasculitis related to imbalances between
the innate and adaptive immune response. Infectious agents or environmental factors
may trigger the disease in genetically predisposed individuals. HLA-B51 is the genetic
factor stronger associated with the disease, although the bases of this association remain
elusive. NK cells have also been implicated in the etiopathogenesis of BD. A family
of NK receptors, Killer-cell Immunoglobulin-like Receptor (KIR), with a very complex
organization, is very important in the education and control of the NK cells by the union
to their ligands, most of them, HLA class I molecules. This study aimed to investigate the
contribution of certain KIR functional polymorphisms to the susceptibility to BD. A total
of 466 BD patients and 444 healthy individuals were genotyped in HLA class I (A, B, and
C). The set of KIR genes and the functional variants of KIR3DL1/DS1 and KIR2DS4 were
also determined. Frequency of KIR3DL1∗004 was lower in patients than in controls (0.15
vs. 0.20, P = 0.005, Pc = 0.015; OR = 0.70; 95% CI 0.54–0.90) in both B51 positive
and negative individuals. KIR3DL1∗004, which encodes a misfolded protein, is included
in a common telomeric haplotype with only one functional KIR gene, KIR3DL2. Both,
KIR3DL1 and KIR3DL2 sense pathogen-associated molecular patterns but they have
different capacities to eliminate them. The education of the NK cells depending on the
HLA, the balance of KIR3DL1/KIR3DL2 licensed NK cells and the different capacities of
these receptors to eliminate pathogens could be involved in the etiopathogenesis of BD.
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INTRODUCTION
Behçet’s disease (BD) [OMIM #109650] is a rare, chronic
and systemic vasculitis characterized by recurrent oral and
genital ulcers, although other clinical manifestations, such as
skin lesions, ocular, gastrointestinal, and neurological disorders
are relatively common. This chronic disorder is an immune-
mediated disease in which imbalances between the innate and
adaptive immune response triggered by infectious agents or
environmental factors in genetically predisposed individuals have
been suggested as the underlying mechanisms of the disease
(1). Among the genetic factors, HLA-B51 has been associated
with the disease in many populations (2); more recently, other
genes related to the immune system such as IL23R, IL10, STAT4,
CCR1, CCR3, KLRC4, ERAP1, TNFAIP3, and FUT2 have been
associated with this disease (3).
Natural killer (NK) cells are lymphocytes of the innate
immune system with several activators and inhibitor receptors
on their surface. Among them, the Killer-cell Immunoglobulin-
like Receptor (KIR) gene family consisted of a set of 15
genes: KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A
KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4,
KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, and KIR3DS1
and 2 pseudogenes: KIR2DP1 and KIR3DP1 located near to
the leukocyte receptor complex in the chromosome 19. The
KIR gene content is variable among individuals being a major
contributor to the KIR diversity in the human population and
the NK cell repertoires (4). At present, 625 genotypes (different
sets of KIR genes) named by numbers assigned sequentially
have been found in the human population1. Based on their gene
content, two kinds of KIR haplotype groups, A and B (that give
rise to the genotypes AA and Bx), have been described. Although
there is no single specific criterion to distinguish them, from a
practical point of view, one individual is considered as Bx when
its set of KIR genes included at least one of the following genes:
2DL2, 2DL5, 3DS1, 2DS1, 2DS2, 2DS3, 2DS5, and it is assigned
as AA when all these genes are absent. The KIR genes encoded
activator or inhibitor molecules, in general, the molecules with
long cytoplasmic tails (L) contains two immune tyrosine-based
inhibitory motifs (ITIM) which transduce inhibitory signals
to the NK cell, whereas the molecules with short cytoplasmic
tails (S) possess a positively charged amino acid residue in their
transmembrane region which allows them to associate with
a DAP12 molecule generating an activation signal (4). The A
Haplotypes have fewer activator genes than haplotypes B, in
fact, the only two activator genes present in AA individuals are
KIR2DS4 and KIR2DL4, but only KIR2DS4 binds HLA classical
molecules. Besides, each KIR gene has a variable number of
alleles, some of them with functional significance. Indeed, a
different expression in the cell membrane of diverse KIR3DL1
alleles, ranging from practically null (in KIR3DL1∗004, which
encodes a misfolded receptor mostly retained inside the cell) to
high expression, or production of soluble forms in the case of
KIR2DS4 (5, 6).
1http://www.allelefrequencies.net/kir6001a.asp
The KIR-ligands are HLA class I molecules and the interaction
between the pair ligand-receptor is fundamental for the
regulation of NK cell activity. All the classical HLA-class I
molecules (HLA-A, B and C) present peptides to the CD8+ T
cells, however, not all of them are ligands of the KIRmolecules. In
this sense, all the HLA-C molecules are ligands of KIR and they
can be grouped as C1 (Asn80) or C2 (Lys80) which are ligands
of KIR2DL2 and KIR2DL1, respectively. Nevertheless, only some
HLA-A and B molecules are KIR ligands, specifically, those
bearing the Bw4 epitope are KIR3DL1 ligands and A3 and A11
have been described to be KIR3DL2 ligands (4). HLA-B51 and
other HLA molecules associated with BD have the Bw4 epitope
and interactions between Bw4 and KIR3DL1 have been proposed
as one of the possible underlying mechanisms to explain the
relationship between HLA class I and BD (7). However, a large
number of common HLA-B alleles encoding molecules with the
Bw4 epitope (e.g., B∗44, B∗49, etc.) have never been associated
with this disease, even those with isoleucine at position 80 (Bw4-
80I), which are the strongly interacting ligands. The Bw4 epitope
spans the residues 77–83 but it has been described that changes
at specific positions in the HLA-B molecule outside this epitope,
in particular, position 97, affect the interaction of Bw4 with
KIR3DL1 and, interestingly, the position 97 of HLA-B has been
found strongly associated with susceptibility to BD (8–10).
With this picture, great complexity and a relative lack of
the knowledge of the polymorphism of the KIR system and
its relationship with its ligands, the objective of this study
was to investigate the contribution of certain KIR functional
polymorphisms to the susceptibility to BD.
MATERIALS AND METHODS
Study Population
The study included a total of 466 BD-unrelated patients
(44.2% males) who fulfilled the 1990 International Study
Group classification criteria for BD (11), and 444 unrelated
healthy individuals (50% males) included as the control
group. All the subjects were Spanish European recruited
from 17 Spanish hospitals across the country. The study was
approved by all local ethical committees of the corresponding
hospitals, and all the study participants gave their written
informed consent to participate. Clinical features of the patient
group were the following: 100% had oral ulcers, 59.4%
genital ulcers, 53.9% uveitis, 42% arthritis, and 21% vascular,
18.2% neurological, 16.3% positive pathergy test, and 15.4%
gastrointestinal involvement.
DNA Extraction
Peripheral blood collected in EDTA tubes was obtained from
the healthy controls, and peripheral blood or saliva served as
starting material from patients. Genomic DNA was extracted
using the QIAamp DNA Mini Kit (Qiagen, Barcelona, Spain)
according to the manufacturer’s recommendations and stored at
−20◦C. The purity of DNA was determined using a NanoDrop
spectrophotometer (Thermo Fisher Scientific, Wilmington, DE,
USA). Only DNA samples having a 260/280 absorbance ratio of
1.7–2.0 and a final concentration of 10–20 ng/µl were considered
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appropriate. A total of 14 DNA samples from saliva were
eliminated because they did not meet these quality criteria.
Genotyping
The HLA class I (A, B, and C) genotyping was carried out using a
PCR-SSOP Luminex method, LABType SSO (One Lambda Inc.,
Canoga Park, CA), according to the manufacturer’s instructions.
Briefly, target DNAs were PCR-amplified using group-specific
primers (HLA-A, -B, or -C) and the biotinylated-PCR products
were denatured and hybridized with specific probes bound
to colored-coded microspheres. Phycoerythrin conjugated to
Streptoavidin was used to label and reveal reactions which were
read in a flow analyzer, LABScanTM100, to identify fluorescent
intensity on each microsphere. The software HLA fusion 2.0
(One Lambda Inc.) was used to assign the HLA typing of each
locus. This method allows a medium resolution genotyping of
each class I HLA gene. After class I genotyping, the samples were
classified as A3/A11, Bw4, Bw4-80I, C1, and C2.
The set of KIR genes presents in each sample was determined
also using a PCR-SSOP Luminex method, KIR SSO Genotyping
Test (One Lambda Inc., Canoga Park, CA), according to
the manufacturer’s instructions. The principle of the method
is the same as that employed for HLA-class I genotyping
with the corresponding group-specific primers and bound-
probes. Also, to distinguish the presence/absence of KIR genes,
this method allows discriminating between some groups of
alleles, specifically, between the group of KIR2DS4 alleles with
the full sequence (KIR2DS4∗001/011/014/015) which encode
functional proteins and the group with a deletion of 22 base
pairs (KIR2DS4∗003/004/006/007/008/009/010/012/013) which
encode non-functional variants (6).
KIR3DL1/S1 individuals were genotyped in the rs149123986
by real-time PCR using TaqMan SNP Genotyping Assays
(Applied Biosystems, Barcelona, Spain) in a LightCycler 480
(Roche, Barcelona, Spain). This single nucleotide polymorphism
(SNP, A/G) allows to distinguish two groups of KIR3DL1
alleles with different expression patterns: the KIR3DL1∗004
(rs149123986G) with a very low or null membrane expression
(3DL1Null) and the rest of alleles (rs149123986A), which have
a normal although variable membrane expression (3DL1Exp)2.
Statistical Analysis
Phenotypic and genotypic frequencies were estimated by direct
counting and distributions were compared using the χ2 test.
This test was applied to check the association of (a) different
ligands: A3/11, B51, Bw4, Bw4-80I, C1, and C2; (b) the KIR
genes, haplotypes and genotypes; (c) the KIR3DL1/DS1 variants
in the full group and the subgroups B51 Bw4, Bw4-80I; and (d)
the KIR2DS4 variants in the total groups and among individuals
AA and Bx and stratified according to the presence/absence
of the combination ligand and receptor. The P-values were
corrected by Bonferroni’s adjustment (Pc) considering the
number of tests in each case. Those comparisons with Pc-
values < 0.05 were considered associated whereas those with
P < 0.05 but with Pc > 0.05 were considered suggestive of
2https://www.ebi.ac.uk/ipd/kir/align.html
association. The odds ratios (ORs) and 95% confidence intervals
(95% CI) were calculated using the web software OpenEpi
(Open Source Epidemiologic Statistics for Public Health, Versión
3.01. www.OpenEpi.com).
RESULTS
HLA Molecules KIR-Ligands
A total of 435 BD patients (96.2%) and 439 controls (98.9%) were
fulfilled genotyped and included in the statistical analysis. The
distribution of different HLA molecules KIR-ligands is displayed
in Table 1. The strongest associations were: HLA-B51, conferring
risk and A3/11, conferring protection. The frequency of A3/11
was decreased in both patient groups, B51 positive and negative
(18 and 21%, respectively, vs. 26 and 33% in their corresponding
controls), although statistical significance was reached only in
the negative group. Bw4 and Bw4-80I confer risk but with a
lower OR than B51. Among the group B51 negative (250 patients
and 370 controls), the distribution of Bw4 and Bw4-80I was
not significantly different in patients and controls (Bw4 76.8%
in patients vs. 76.2 in controls; Bw4-80I 56.0% in patients vs.
56.2% in controls, P > 0.05 in both cases). No differences in the
distribution of C1 and C2 were detected in any case.
KIR Genes
The distribution of the KIR genes in our cohort of patients
and controls is summarized in Table 2. All the KIR genes
and pseudogenes were detected in this study and four of
them, corresponding to the centromeric (3DL3 and 3DP1) and
telomeric (2DL4 and 3DL2) framework genes, were found in all
the samples. The distribution of genes was similar in patients
and controls and statistically significant differences were not
reached in any case. Regarding the distribution of the KIR
haplotypes, Bx was the most common in both groups and
no significant differences between patients and controls were
observed. Concerning the KIR genotypes, a total of 51 genotypes
were found in our cohort, but only 12 had a frequency upper 2%
in at least one of the groups. The genotype 2 was slightly less
TABLE 1 | Distribution of HLA molecules KIR-ligands in Spanish BD patients and
controls.
HLA BD (%) Controls (%) P OR (95% CI)
N = 435 N = 439
B51 185 (42.5) 69 (15.7) <10−7 3.96 (2.89–5.48)
A3/11a 87 (20.0) 140 (31.9) <10−4 0.53 (0.39–0.73)
Bw4 377 (86.7) 351 (80.0) 0.008 1.63 (1.13–2.35)
Bw4-I80 325 (74.7) 277 (63.1) 0.0001 1.73 (1.29–2.31)
C1 329 (75.6) 351 (79.9) >0.05
C2 313 (71.9) 302 (68.8) >0.05
C1C1 122 (28.0) 137 (31.2) >0.05
C1C2 207 (47.6) 214 (48.7) >0.05
C2C2 106 (24.4) 88 (20.0) >0.05
aB51 positive group: 34 patients and 18 controls A3/11 positive (p = 0.09); B51 negative
group: 53 patients and 122 controls A3/11 positive (p = 0.001).
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TABLE 2 | Distribution of KIR genes in Spanish BD patients and healthy controls.
KIR BD Controls P Pc
n = 435 (%) n = 439 (%)
Genes
2DL1 416 (95.6) 422 (96.1)
2DL2 270 (62.1) 267 (60.8)
2DL3 373 (85.7) 382 (87.0)
2DL4 435 (100) 439 (100)
2DL5A/2DL5B 241 (55.4) 261 (59.4)
2DP1 416 (95.6) 423 (96.4)
2DS1 174 (40.0) 194 (44.2)
2DS2 269 (61.8) 262 (59.7)
2DS3 156 (35.9) 153 (34.8)
2DS4 408 (93.8) 421 (95.9)
2DS5 141 (32.4) 168 (38.3)
3DL1 409 (94.0) 422 (96.1)
3DS1 181 (41.6) 192 (43.7)
3DL2 435 (100) 439 (100)
3DL3 435 (100) 439 (100)
3DP1 435 (100) 439 (100)
Haplotypes n = 435 (%) n = 439 (%)
AA 109 (25.1) 100 (22.8)
Bx 326 (74.9) 339 (77.2)
Genotypes n = 435 (%) n = 439 (%)
1 109 (25.1) 100 (22.8)
2 38 (8.7) 62 (14.1) 0.01 >0.05
3 23 (5.3) 21 (4.8)
4 65 (14.9) 63 (14.3)
5 39 (9.0) 45 (10.2)
6 26 (6.0) 36 (8.2)
7 18 (4.1) 16 (3.6)
13 10 (2.3) 4 (0.9)
70 9 (2.1) 5 (1.1)
71 8 (1.84) 12 (2.7)
72 14 (3.2) 11 (2.5)
73 12 (2.8) 10 (2.3)
The resta 64 (14.7) 54 (12.3)
aGenotypes with a frequency lower than 2%.
frequently represented in patients than in controls (8.7 vs. 14.1%,
respectively, P = 0.01, Pc > 0.05; OR 0.58; 95% CI 0.38–0.89).
Functional KIR Polymorphyms
Data regarding the polymorphism of KIR3DL1/S1 are displayed
in Table 3. The distribution of individuals KIR3DL1/S1 was not
significantly different in patients and controls (KIR3DL1+DS1+
35.6 vs. 39.9%, KIR3DL1+DS1– 58.3 vs. 56.3%, KIR3DL1-DS1+
6.0 vs. 3.9%, respectively). Nevertheless, the distribution of the
genotypes of rs149123986 was significantly different in both
groups (p = 0.01 in 2 × 3 contigency Table) with an over-
representation of AA in patients (73.5% vs. 64.3 in controls, Pc=
0.006; OR = 1.54; 95% CI 1.16–2.07) and a down-representation
of AG (23.0 vs. 31.7%, Pc= 0.015, OR= 0.65; 95% CI 0.48–0.88).
The distribution of the individuals in the six possible groups
taking into account both, the KIR3DL1/S1 and the rs149123986,
was different in patients and controls (p = 0.002 in 2 × 6 Table)
with down-representation of 3DL1Null/3DL1 (6.2 vs. 11.4%, p=
0.007, Pc = 0.042; OR = 0.51; 95% CI 0.32–0.84) and a trend
to an over-representation of 3DL1Exp/3DL1Exp (38.1 vs. 31.9%,
p = 0.052) individuals among patients. The distribution of the
three allele groups: 3DL1Exp, 3DL1Nul, and 3DS1 was different
in patients and control (p = 0.01, in 2 × 3 contigency Table)
having the group of patients a decreased frequency of 3DL1Null
(0.15 vs. 0.20, P = 0.005, Pc = 0.015; OR = 0.70; 95% CI 0.54–
0.90) and a slight increased frequency of 3DL1Exp (0.61 vs. 0.56,
P = 0.03, Pc > 0.05). Results were similar among B51 positive
and negative individuals with a suggestive down-representation
of 3DL1Null/3DLS1 in both groups (B51positive: 5.9% in patients
vs. 15.9% in controls P = 0.009 Pc > 0.05; OR = 0.34; 95% CI
0.13–0.83 and B51 negative: 6.4% in patients vs. 10.5% in controls
P = 0.04 Pc > 0.05; OR= 0.58; 95% CI 0.3–1.05) (Table 4).
Regarding the deletion of 22 bp of 2DS4, differences in the
distribution of individuals with at least one copy of the 2DS4Full
between patients and controls were not detected (42.7 vs. 37.5%,
P = 0.13). Since 2DS4 is the only activator binding classical HLA
molecules in AA individuals, patients and controls were stratified
according to their haplotype group in AA or Bx but no differences
were detected (Data not showed).
DISCUSSION
The main finding of this study is the association of the
KIR3DL1∗004 with susceptibility to BD. This allele is protective
in the development of the disease and, according to our results,
its effect is independent of HLA-B51.
Previous studies analyzed the relationship between the
distribution of the KIR genes and the disease. Similarly to our
results, no differences between patients and controls have been
reported in these studies (12–15). Only one of these studies,
performed in the Iranian population, investigated KIR genotypes.
That study reported a different distribution of various KIR
genotypes, including genotype 2, although the direction of the
association was contrary to that found in the present study (15).
KIR3DL1/DS1 has focused on interest because of its function
as the receptor of the Bw4 epitope. The distribution of KIR3DL1
and 3DS1 in BD was evaluated in a large cohort of Turkish.
Similarly to our results, no association was found in the
whole cohort neither in subgroups with B51, Bw4, or Bw4-
80I (16) but this study did not investigate variants on this
gene. Variants in KIR3DL1 have been reported as associated
with the disease in two high throughput studies (10, 17),
although none of them was designed to investigate the possible
involvement of functional variants in this disease. Very recently,
during the submission of this paper, a study that addresses
this question in a smaller cohort composed of ethnically-
mixed patients and controls was published (18). The main
conclusion of that study is the same as ours, an association
of the functional alleles of KIR3DL1, independent of HLA-
B51 with the disease. Nevertheless, they are some discrepancies
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TABLE 3 | Frequency of the KIR3DL1/DS1 functional polymorphism in BD patients and controls.
KIR rs149123986 BD Controls P Pc OR (95%CI)
3DL1 3DS1 n = 435 % n = 439 %
+ – AA 3DL1Exp/3DL1Exp 166 38.1 140 31.9 0.05 >0.05
+ – AG 3DL1Exp/3DL1Null 74 17.0 89 20.3
+ + AA 3DL1Exp/3DS1 128 29.4 125 28.5
+ – GG 3DL1Null/3DL1Null 14 3.2 18 4.1
+ + AG 3DL1Null/3DS1 27 6.2 50 11.4 0.007 0.042 0.51 (0.32–0.84)
- + AA 3DS1/3DS1 26 6.0 17 3.9
AF AF
3DL1Exp 534 0.61 494 0.56 0.03 >0.05
3DL1Null 129 0.15 175 0.20 0.005 0.015 0.7 (0.54–0.90)
3DS1 207 0.24 209 0.24 >0.05 >0.05
AF, allelic frequency. Bold values are those statistically significant after correction.
TABLE 4 | Frequency of the KIR3DL1 functional polymorphism in BD patients and
controls stratified according to the HLA-B51.
B51+ B51–
BD Controls BD Controls
185 69 250 370
n % n % n % n %
3DL1Exp/3DL1Exp 76 41.1 25 36.2 90 36.0 115 31.1
3DL1Exp/3DL1Null 28 15.1 11 15.9 46 18.4 78 21.1
3DL1Exp/3DS1 53 28.7 19 27.5 75 30.0 106 28.6
3DL1Null/3DL1Null 7 3.8 3 4.3 7 2.8 15 4.1
3DL1Null/3DS1 11 5.9 11 15.9 16 6.4 39 10.5
3DS1/3DS1 10 5.4 0 0.0 16 6.4 17 4.6
3DL1Exp 233 0.63 80 0.58 301 0.60 414 0.56
3DL1Null 53 0.14 28 0.20 76 0.15 147 0.20
3DS1 84 0.23 30 0.22 123 0.25 179 0.24
in the associated genotypes between these two studies. When
the allele frequencies of the study by Petrushkin et al. are
deduced of their data, results are similar to ours regarding the
allele KIR3DL1∗004, which is underrepresented in patients (with
similar OR), although the statistical significance is only reached
in our cohort. Nevertheless, we have opposite results concerning
KIR3DL1Exp and KIR3DS1. In our cohort, the alleles that
encode KIR3DL1Exp are significantly overrepresented among
patients whereas, in its cohort, it is KIR3DS1 which tends
to be overrepresented among patients. In our opinion, the
distribution of the allelic frequencies reinforces the idea of
association with the allele KIR3DL1∗004. Discrepancies could be
due to different reasons, among them, methods used in KIR3DL1
genotyping, approaches, stratification of cohorts with a relatively
small number of individuals and ethnical differences. Besides,
there are previous studies in other class-I pathologies such as
psoriatic disease (PD) and ankylosing spondylitis (AS), in which
a protective association of the KIR3DL1∗004 allele has been
reported (19–21).
KIR3DL1∗004 encodes a misfolded receptor which is retained
in the cell, although it has been described that a small quantity
of folded protein can be exported to the membrane (22). One
possible explanation to the protective effect of KIR3DL1∗004
in these pathologies is that this misfolded molecule retains
intracellularly the corresponding class I-risk molecules. In
this case, differences in the distribution of KIR3DL1∗004
among patients with and without the risk molecule would
be expected, nevertheless, no differences were found in the
present study neither in other pathologies (20, 21, 23) and
no evidence supporting the intracellular interaction between
KIR3DL1 and MHC class I molecules have been found (5).
Interestingly, KIR3DL1∗004 is within a common telomeric
haplotype Tel-A1-V which, also, bears two alleles encoding
secreted receptors, KIR2DL4∗008 and KIR2DS4∗006 and another
that encodes a membrane receptor KIR3DL2∗003/005/011/020
(24)3. Therefore, this Tel-A1-V haplotype, protective in BD,
carries non-functional alleles with the only exception of
KIR3DL2. Consequently, KIR3DL1∗004 could be a marker of the
Tel-A1-V haplotype and the protective association found in our
study could be explained by the fact that KIR3DL2 is the only
functional gene in this haplotype.
KIR3DL2 is an inhibitor framework gene, found in 100% of
the population and it has many allelic forms encoding many
different proteins (161 and 111, respectively, in the last database),
the relative expression levels of these different proteins are
unknown. The KIR3DL2 HLA-ligands are A3 and A11 and there
is some evidence that KIR3DL2 can bind these HLA molecules
in vivo (25). The education of the NK cells is based on the
interaction between the inhibitory receptors and the self-MHC-
I molecules, only those individuals bearing the HLA-ligand
molecules have licensed NK cells that express the corresponding
receptor and therefore, only the individuals A3 and A11 have
mature NK cells expressing KIR3DL2. Noticeably, similarly to
the findings in the present cohort, different studies in several
populations have found a protective association of HLA-A3 with
BD, independent of HLA-B51 (9, 10, 26). This protective effect
3https://www.ebi.ac.uk/ipd/kir/sequenced_haplotypes.html
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of HLA-A3, not yet explained, could be based on the presence of
licensed KIR3DL2 NK cells in these individuals.
KIR molecules having 3 extracellular domains (KIR3DL1 and
KIR3DL2) are pattern recognition receptors (PRR), they sense
pathogen-associated molecular patterns (PAMPs), specifically
single-stranded microbial DNA molecules containing CpG
motifs (CpG-ODN). KIR3DL2 binds CpG-ODN by the D0
domain and the complexes are internalized and recognized
by TLR9 located in the endosomal compartment what results
in cell activation. Nevertheless, in spite of KIR3DL1 binds
CpG-ODN, the complexes are not internalized (27). Thus,
one possible explanation to the protective effect of the Tel-
A1-V haplotype is that the lack of expression of KIR3DL1
in these individuals permits a better efficiency to eliminate
pathogens by KIR3DL2 NK cells. In other words, NK cells
of individuals with the KIR3DL1Exp would be lesser efficient
in eliminating pathogens resulting in a perpetuation of the
release of inflammatory cytokines. In this sense, a protective
effect of KIR3DL1∗004 against the progression of the VIH
infection to AIDS has been described (28). This mechanism
would explain why the association is independent of B51
and Bw4 in our study but also psoriasis. Moreover, some
HLA-Bw4 molecules, such as B27 (associated with ankylosis
spondylitis) and B51 could be more efficient to license KIR3DL1
NK cells and this could be related to its association with
inflammatory diseases. In this sense, the activity of ERAP1,
an enzyme that has been related in an epistatic way with the
HLA molecules involved in these pathologies and that can
conditioner the repertoire of peptides binding to them, could
modify the role of the diverse HLA-Bw4 molecules in these
diseases (29).
Lastly, the Tel-A1-V haplotype includes KIR2DS4∗006, which
has the deletion of 22 base pairs, but according to our results, this
deletion does not influence the disease susceptibility.
In conclusion, our results suggest a protective role of a
telomeric KIR haplotype with only one functional gene in BD.
Therefore, the education of the NK cells depending on the HLA,
the balance of licensed KIR3DL1/KIR3DL2 NK cells and the
different capacities of these receptors to eliminate pathogens
could be involved in the etiopathogenesis of BD.
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